Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALYPSO: Phase 3 Eneboparatide in Chronic Hypoparathyroidism
jRCT2051240158Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2024
- Modality
- Small Molecules, Peptides
01
Overview
Phase 3, randomised, double-blind trial in chronic hypoparathyroidism comparing Eneboparatide with Placebo (2 arms). Primary endpoint: Primary composite endpoint at Week 24. Started Nov 2024; status: active, not recruiting.
02
Drugs
eneboparatide
03
Conditions
chronic hypoparathyroidism
Beyond the preview
Go deeper on jRCT2051240158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240158.